
SRRK Stock Forecast & Price Target
SRRK Analyst Ratings
Bulls say
Scholar Rock Holding is launching its first commercial product, apitegromab, which treats Spinal Muscular Atrophy, and has received positive feedback from the FDA regarding its manufacturing facilities. This milestone, along with potential European approval in mid-2026, positions the company for significant revenue growth potential. Additionally, the company is also developing a subcutaneous formulation of apitegromab to expand patient access, and has a diverse pipeline targeting other neuromuscular diseases. Overall, with confidence in the company's manufacturing issues being resolved, we anticipate a successful launch of apitegromab and see significant upside potential for the company.
Bears say
Scholar Rock Holding is projected to have a near-term BLA resubmission and potential FDA approval for apitegromab, a significant regulatory de-risking event that could support a 2026 launch and positive launch dynamics. This is further supported by the company's progress on early-stage programs and additional fill-finish facility, but risks such as weight-based pricing dynamics and sluggish initial uptake could temper the initial trajectory. Given the projected launch and potential approval, a neutral outlook may be more appropriate for investors evaluating the company's potential.
This aggregate rating is based on analysts' research of Scholar Rock Holding Corp and is not a guaranteed prediction by Public.com or investment advice.
SRRK Analyst Forecast & Price Prediction
Start investing in SRRK
Order type
Buy in
Order amount
Est. shares
0 shares